BAIAP2 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line, designed for targeted disruption of the BAIAP2 (IRSp53) gene. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous pool of edited cells that circumvents clonal selection artifacts and preserves population-level phenotypic diversity. By ablating BAIAP2 expression, researchers can interrogate the scaffold protein’s role in actin cytoskeleton organization, cell migration, and receptor-mediated signaling cascades, providing a versatile platform for mechanistic studies in oncology and cell biology.
The HT29 host cell line originates from a primary colorectal adenocarcinoma isolated from a 44-year-old female patient and serves as a well-characterized epithelial model of colorectal cancer. HT29 cells exhibit polarized monolayer formation, aberrant Wnt/??-catenin and EGFR signaling, and intrinsic invasive properties, making them a clinically relevant background for investigating tumor cell motility and metastasis. The epithelial origin of HT29 further allows analysis of BAIAP2 function in the context of cell polarity, adhesion, and apical-basolateral membrane dynamics, which are often dysregulated during cancer progression.
BAIAP2 functions as a scaffold adaptor that directly couples activated Rac1 and Cdc42 GTPases to the WAVE regulatory complex, facilitating Arp2/3-dependent actin nucleation and the formation of lamellipodia and filopodia. It interacts with WAVE2, Abi1, IRTKS, and EPS8, and is positioned downstream of receptors such as EGFR, PDGFR, and the insulin receptor, which trigger Rac1 activation. Upon stimulation, BAIAP2 orchestrates insulin-mediated GLUT4 vesicle translocation and promotes membrane protrusion necessary for directional cell migration. Thus, BAIAP2 integrates signals from growth factor and integrin pathways to control cytoskeletal remodeling, acting as a nexus between extracellular cues and the actin polymerization machinery.
In HT29 colorectal adenocarcinoma cells, knockout of BAIAP2 disrupts Rac1/Cdc42-to-WAVE signaling, leading to impaired actin cytoskeletal remodeling and reduced formation of migratory structures. This is expected to attenuate cell motility, invasion through Matrigel, and chemotactic responses, all of which are critical for metastatic dissemination. Consequently, this model enables dissection of BAIAP2-dependent invasion mechanisms and evaluation of how loss of this scaffold impacts tumor cell plasticity and responsiveness to promigratory stimuli like EGF or insulin.
The BAIAP2 knockout polyclonal HT29 cells are suited for functional assays including wound healing migration assays, Matrigel invasion assays, and immunofluorescence visualization of F-actin-rich lamellipodia and filopodia. They also support quantitative glucose uptake assays to assess insulin signaling, Rac1 activation assays, and co-immunoprecipitation for mapping protein interactions. This product facilitates research into colorectal cancer metastasis, insulin resistance, and cytoskeletal dynamics, serving as a robust tool for validating anti-metastatic drug targets. For further information, please contact Ascent Research.
